PDL BIOPHARMA | 4,799 Euro | -0,099 -2,02 % | |
| WKN: A0H1J1 ISIN: US69329Y1047 Ticker-Symbol: PDL | Frankfurt | 10.02.12 | 16:14 Uhr |
Branche PharmaAktienmarkt NASDAQ Biotech |
|
| Zeit | Aktuelle Nachrichten | Leser | Medien | |
|---|---|---|---|---|
| 07.02. | PDL BioPharma to Present at the 14th Annual BIO CEO & Investor Conference | 8 | PR Newswire | |
| INCLINE VILLAGE, Nev., Feb. 7, 2012 /PRNewswire/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled... Mehr lesen zu: PDL BioPharma to Present at the 14th Annual BIO CEO & Investor Conference | ||||
| 02.02. | PDL BioPharma Announces Exchange of Its 2.875% Convertible Senior Notes due February 15, 2015 | 46 | PR Newswire | |
| INCLINE VILLAGE, Nev., Feb. 2, 2012 /PRNewswire/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has entered into separate privately negotiated exchange agreements under which it... Mehr lesen zu: PDL BioPharma Announces Exchange of Its 2.875% Convertible Senior Notes due February 15, 2015 | ||||
| 30.01. | Highest Revenue Per Employee in the Biotechnology Industry Detected in Shares of PDL BioPharma | 5 | SmarTrend | |
| 25.01. | Relatively Low Forward P/E Ratio Detected in Shares of PDL BioPharma in the Biotechnology Industry | 4 | SmarTrend | |
| 24.01. | PDL BioPharma Announces 2012 Regular Quarterly Dividends | 54 | PR Newswire | |
| INCLINE VILLAGE, Nev., Jan. 24, 2012 /PRNewswire/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that its board of directors has declared that the regular, quarterly dividends to be paid... Mehr lesen zu: PDL BioPharma Announces 2012 Regular Quarterly Dividends | ||||
| 13.01. | PDL BioPharma's CEO Presents at 30th Annual JP Morgan Healthcare Conference (Transcript) | 8 | Seeking Alpha | |
| 06.01. | PDL BioPharma Announces Settlement and Final Results of its Exchange Offer | 94 | PR Newswire | |
| INCLINE VILLAGE, Nev., Jan. 5, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the settlement and final results of its offer to exchange up to $180,000... Mehr lesen zu: PDL BioPharma Announces Settlement and Final Results of its Exchange Offer | ||||
| 05.01. | PDL BioPharma to Present at the 30th Annual JP Morgan Healthcare Conference | 8 | PR Newswire | |
| INCLINE VILLAGE, Nev., Jan. 5, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive... Mehr lesen zu: PDL BioPharma to Present at the 30th Annual JP Morgan Healthcare Conference | ||||
| 04.01. | PDL BioPharma (PDLI) Gets 93.9% Response in Notes Exchange Offer | 7 | StreetInsider.com | |
| 04.01. | PDL BioPharma Announces Expiration and Preliminary Results of its Exchange Offer | 50 | PR Newswire | |
| INCLINE VILLAGE, Nev., Jan. 3, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the expiration and preliminary results of its offer to exchange up to $180... Mehr lesen zu: PDL BioPharma Announces Expiration and Preliminary Results of its Exchange Offer | ||||
| 29.12. | PDL BioPharma has the Highest Revenue Per Employee in the Biotechnology Industry | 7 | SmarTrend | |
| 19.12. | PDL BioPharma Sees Q4 Revenues Drop | 75 | AFX News | |
| WASHINGTON (dpa-AFX) - PDL BioPharma Inc. (PDLI) announced Monday its
fourth-quarter revenues guidance, with its estimate of approximately $72 million
lower than the prior-year result of... Mehr lesen zu: PDL BioPharma Sees Q4 Revenues Drop | ||||
| 19.12. | PDL BioPharma Provides Fourth Quarter 2011 Revenue Guidance of $72 Million | 25 | PR Newswire | |
| INCLINE VILLAGE, Nev., Dec. 19, 2011 /PRNewswire/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the fourth quarter ending December 31, 2011 of approximately... Mehr lesen zu: PDL BioPharma Provides Fourth Quarter 2011 Revenue Guidance of $72 Million | ||||
| 15.12. | PDL BioPharma Completes Regular Quarterly Dividend Payment | 25 | PR Newswire | |
| INCLINE VILLAGE, Nev., Dec. 15, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the December 15, 2011, regular quarterly dividend payment... Mehr lesen zu: PDL BioPharma Completes Regular Quarterly Dividend Payment | ||||
| 12.12. | PDL BioPharma CFO Christine Larson Departs | 83 | AFX News | |
| WASHINGTON (dpa-AFX) - PDL BioPharma Inc. (PDLI) announced the resignation
of Christine Larson from her position as vice president and chief financial
officer of PDL, effective as of December... Mehr lesen zu: PDL BioPharma CFO Christine Larson Departs | ||||
| 12.12. | PDL BioPharma Corrects Adjusted Conversion Rates For Convertible Notes | 30 | AFX News | |
| WASHINGTON (dpa-AFX) - PDL BioPharma Inc. (PDLI) corrected its
earlier-announced adjusted conversion rate for its 2.875% Convertible Senior
Notes due February 15, 2015, to 155.396 shares... Mehr lesen zu: PDL BioPharma Corrects Adjusted Conversion Rates For Convertible Notes | ||||
| 12.12. | PDL BioPharma Announces Departure of Chief Financial Officer | 22 | PR Newswire | |
| INCLINE VILLAGE, Nev., Dec. 12, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that Christine Larson has resigned her position as vice president and chief financial... Mehr lesen zu: PDL BioPharma Announces Departure of Chief Financial Officer | ||||
| 12.12. | PDL BioPharma (PDLI) Corrects Convertible Notes Coversion Rate for Upcoming Dividend | 3 | StreetInsider.com | |
| 12.12. | PDL BioPharma Corrects Its Adjusted Conversion Rates for Its Convertible Notes | 12 | PR Newswire | |
| INCLINE VILLAGE, Nev., Dec. 12, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today corrected its earlier-announced adjusted conversion rate for its:
2.875% Convertible... Mehr lesen zu: PDL BioPharma Corrects Its Adjusted Conversion Rates for Its Convertible Notes | ||||
| 07.12. | PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes | 26 | PR Newswire | |
| INCLINE VILLAGE, Nev., Dec. 7, 2011 /PRNewswire/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for its:
2.875% Convertible Senior Notes... Mehr lesen zu: PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes | ||||
Startseite • Nachrichten • Aktienkurse • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Chartanalysen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage
